Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.

By R. Keefe, Robert M. Bilder, S. Davis, Philip D. Harvey, B. Palmer, J. Gold, H. Meltzer, Michael F. Green, G. Capuano, T. Scott Stroup and 7 more. 2007

1,086 citations recorded by the source corpus.

Subfields: Pharmacology, Psychiatry and Mental health

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Pharmacology

In Psychiatry and Mental health

Citations in the corpus

Reinforcement Learning in Healthcare: A Survey (2019, methodology): “]. c) Schizophrenia: RL methods have been also used to derive optimal DTRs in treatment of schizophrenia, using data from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study [176], which was an 18-month study divided into two main phases of treatment. An in-depth case study”
Animal models of schizophrenia (2011, background): “However, while positive symptoms are currently treated to a varying degree by typical and atypical antipsychotics, the negative, and in particular, the cognitive impairments, remain resistant to treatment with current antipsychotics even after remission of the psychosis (Nuechterlein et al., 2004; K”
Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment (2023, background): “Identifying whether variation in cognitive performance in schizophrenia relates to variation in the severity and nature of the illness, as opposed to variation in premorbid function also has relevance for whether precision psychiatry approaches (which aim to stratify patients according to differing ”
The diagnosis of mental disorders: the problem of reification. (2010, result): “As was already apparent, albeit only documented later in a large trial (Keefe et al. 2007), existing treatments had only modest therapeutic effects on cognitive symptoms of schizophrenia.”
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Update 2012 on the acute treatment of schizophrenia and the management of treatment resistance (2012, background): “A 52-week double-blind, multicenter study with 400 schizophrenia patients early in the course of their disease showed for olanzapine, quetiapine and risperidone modest signifi cant improvements in neurocognition, with no differences between drugs (Keefe et al. 2007b).”
Schizophrenia, "just the facts" 4. Clinical features and conceptualization. (2009, positive): “…someof this is attributable to practice effects, with no substantial differences noted between first- and second-generation antipsychotic agents (Keefe et al., 2007) controlling for differences in extrapyramidal side-effects (Tandon et al., 2008c); (vii) the course of cognitive function through…”